According to Zacks, "OXiGENE, Inc. is an international biopharmaceutical company engaged principally in research into and the development of products for use in the treatment of cancer and other major diseases. " Separately, HC Wainwright lowered their target price on shares of OXiGENE from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, October 2nd.